The COVID-19/Influenza A+B Antigen Combo Rapid Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2, influenza A and influenza B viral nucleocapsid protein antigens in nasopharyngeal swab from individuals suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider. Symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar.
Nasopharyngeal Swab
| Catalog No. | Specifications | Reaction Time | Sensitivity | Specificity | Storage Condition | Shelf Life | Certification |
|---|---|---|---|---|---|---|---|
| IrIDq325-B025 | 25 tests/box | 15 mins | For COVID-19 Antigen: 97.7% (95%CI: 93.5%～99.2%) For Influenza A: 89.0% (95%CI: 79.8%~94.3%) For Influenza B: 84.7% (95%CI: 73.5%~91.8%) | For COVID-19 Antigen: 99.8% (95%CI: 98.8%～100%) For Influenza A: 99.8% (95%CI: 99.0%~100%) For Influenza B: 99.6% (95%CI: 98.7%~99.9%) | 4-30℃ | 24 months | CE |
This product cannot be sold in the United States.
